ILMN · Illumina, Inc. - Financials

Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.

Price · ILMN

1Y 3Y 5Y Max

Annual Quarterly

Income Statement

Line item	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	$4.34B	$4.37B	$4.50B	$4.58B	$4.53B	$3.24B
Cost of Revenue	$1.47B	$1.51B	$1.76B	$1.61B	$1.37B	$1.04B
Gross Profit	$2.87B	$2.86B	$2.74B	$2.97B	$3.15B	$2.20B
R&D	$967.00M	$1.17B	$1.35B	$1.32B	$1.19B	$682.00M
SG&A	$1.09B	$1.09B	$1.61B	$1.30B	$2.09B	$941.00M
Total Operating Expenses	$2.06B	$3.69B	$3.81B	$7.15B	$3.28B	$1.62B
D&A	$270.00M	$354.00M	$432.00M	$394.00M	$251.00M	$187.00M
Operating Income	$807.00M	($833.00M)	($1.07B)	($4.18B)	($123.00M)	$580.00M
Interest Expense	$101.00M	$26.00M	$77.00M	$26.00M	$61.00M	$49.00M
Income Tax	$236.00M	$44.00M	$44.00M	$68.00M	$122.00M	$200.00M
Net Income	$850.00M	($1.22B)	($4.40B)	($4.40B)	$762.00M	$656.00M
EPS - Basic	$5.47	($7.69)	($7.14)	($27.24)	$4.93	$4.36
EPS - Diluted	$5.45	($7.69)	($7.14)	($27.24)	$4.90	$4.33

Balance Sheet

Line item	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Cash & Equivalents	$1.42B	$1.13B	$1.05B	$2.01B	$1.23B	$1.81B
Accounts Receivable	$854.00M	$735.00M	$734.00M	$671.00M	$648.00M	$487.00M
Inventory	$564.00M	$547.00M	$587.00M	$568.00M	$431.00M	$372.00M
Accounts Payable	$240.00M	$221.00M	$245.00M	$293.00M	$332.00M	$192.00M
Current Assets	$3.29B	$2.75B	$2.61B	$3.56B	$2.71B	$4.48B
Total Assets	$6.64B	$6.30B	$10.11B	$12.25B	$15.22B	$7.58B
Current Liabilities	$1.58B	$1.55B	$1.57B	$2.77B	$1.09B	$1.24B
Long-term Debt	-	-	-	-	-	$673.00M
Total Liabilities	-	-	-	-	-	-
Stockholders' Equity	$2.72B	$2.37B	$5.75B	$6.60B	$10.74B	$4.69B
Retained Earnings	($392.00M)	($1.24B)	($19.00M)	$1.14B	$5.49B	$4.72B

Cash Flow

Line item	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Operating Cash Flow	$1.08B	$837.00M	$478.00M	$392.00M	$545.00M	$1.08B
Investing Cash Flow	($55.00M)	($178.00M)	($231.00M)	($591.00M)	($1.07B)	($554.00M)
Financing Cash Flow	($744.00M)	($570.00M)	($1.21B)	$1.00B	($51.00M)	($766.00M)
CapEx	$148.00M	$128.00M	$195.00M	$286.00M	$208.00M	$189.00M
Free Cash Flow	$931.00M	$709.00M	$283.00M	$106.00M	$337.00M	$891.00M

Ratios

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Profitability
Gross margin	66.1%	65.4%	60.9%	64.8%	69.7%	68.0%
Operating margin	18.6%	-19.1%	-23.7%	-91.2%	-2.7%	17.9%
EBITDA margin	24.8%	-11.0%	-14.1%	-82.6%	2.8%	23.7%
Net margin	19.6%	-28.0%	-97.8%	-96.1%	16.8%	20.3%
Free cash flow margin	21.4%	16.2%	6.3%	2.3%	7.4%	27.5%
FCF / Net income	1.10	-0.58	-0.06	-0.02	0.44	1.36
R&D / Revenue	22.3%	26.7%	30.1%	28.8%	26.2%	21.1%
SG&A / Revenue	25.0%	25.0%	35.8%	28.3%	46.2%	29.1%
Effective tax rate	21.7%	-	-	-	13.8%	23.4%
Return on assets	12.8%	-19.4%	-43.6%	-35.9%	5.0%	8.6%
Return on equity	31.2%	-51.5%	-76.7%	-66.7%	7.1%	14.0%
Return on invested capital	-	-	-	-	-	8.3%
Liquidity
Current ratio	2.08	1.78	1.66	1.28	2.48	3.60
Quick ratio	1.72	1.42	1.29	1.08	2.09	3.30
Cash ratio	0.89	0.73	0.67	0.73	1.13	1.45
Leverage
Debt / Equity	-	-	-	-	-	0.14
Debt / Assets	-	-	-	-	-	0.09
Debt / EBITDA	-	-	-	-	-	0.88
Interest coverage	8.0x	-32.0x	-13.9x	-160.7x	-2.0x	11.8x
Equity multiplier	2.44	2.66	1.76	1.86	1.42	1.62
Liabilities / Assets	-	-	-	-	-	-
Efficiency
Asset turnover	0.65	0.69	0.45	0.37	0.30	0.43
Inventory turnover	2.61	2.76	3.00	2.84	3.18	2.78
Days sales outstanding	72d	61d	59d	53d	52d	55d
Days inventory outstanding	140d	132d	122d	129d	115d	131d
Days payable outstanding	59d	53d	51d	66d	88d	68d
Cash conversion cycle	152d	140d	130d	116d	79d	118d
Valuation
P / E	24.1x	-	-	-	75.5x	83.1x
P / B	7.5x	9.0x	3.7x	4.7x	5.2x	11.3x
P / S	4.7x	4.9x	4.8x	6.7x	12.3x	16.4x
EV / EBITDA	17.7x	-	-	-	427.0x	68.0x
Growth
Revenue growth (YoY)	-0.7%	-2.9%	-1.7%	1.3%	39.7%	-8.6%
Revenue CAGR (3y)	-1.8%	-1.1%	11.6%	9.0%	18.0%	5.6%
Revenue CAGR (5y)	6.0%	4.3%	10.4%	10.7%	13.5%	7.9%
Gross profit growth (YoY)	0.3%	4.3%	-7.7%	-5.8%	43.2%	-10.7%
Operating income growth (YoY)	-	22.1%	74.4%	-3297.6%	-	-41.1%
Net income growth (YoY)	-	72.2%	0.0%	-	16.2%	-34.5%
EPS growth (YoY)	-	-7.7%	73.8%	-	13.3%	-35.8%
EPS CAGR (3y)	-	-	-	-	-4.1%	-4.2%
EPS CAGR (5y)	4.7%	-	-	-	9.8%	6.9%
FCF growth (YoY)	31.3%	150.5%	167.0%	-68.5%	-62.2%	5.8%
FCF CAGR (5y)	0.9%	-3.4%	-19.7%	-28.4%	-4.6%	11.5%
Book value growth (YoY)	14.7%	-58.7%	-12.9%	-38.6%	128.8%	1.8%

Sales by segment

From XBRL dimensional facts in the 10-K period ending 2025-12-28.

Business segments

$8.69B total

Core Illumina$4.34B · 50.0%

Sequencing$3.98B · 45.9%

Microarray$358.00M · 4.1%

Product / service

$7.75B total

Product$3.71B · 47.9%

Consumables$2.94B · 37.9%

Service$634.00M · 8.2%

Instruments$465.00M · 6.0%

Geographic

$6.59B total

Americas$2.41B · 36.5%

US$2.24B · 34.1%

Europe$1.26B · 19.2%

Asia Pacific Middle East And Africa$430.00M · 6.5%

CN$243.00M · 3.7%

Stability scores

Piotroski F-score

FY 2025 · 9-point quality

7/9

Strong

✓Net income positive
✓Operating cash flow positive
✓ROA improved YoY
✓Cash flow > net income
-Long-term debt decreased
✓Current ratio improved
✓No share dilution
✓Gross margin improved
✗Asset turnover improved

Peer comparison

Same SIC group: Laboratory Analytical Instruments

Company	Revenue (last FY)	Net margin	ROE
AVTR	$6.55B	-8.1%	-9.5%
QTRX	$138.90M	-77.1%	-36.2%
A	-	-	-
CTKB	$201.49M	-33.0%	-19.5%
EYPT	$31.37M	-739.4%	-75.8%

Comparing ILLUMINA against the 5 most active filers in the same SIC group.